The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

The Department of Health and Social Care is gauging whether AI technology can increase the number of patients screened by each radiologist.

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Thirty patients have received the gene therapy within a clinical trial and early-access program, and the foundation also hopes to seek approval in the US.